Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Share-based Compensation (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Share-based Compensation for 16 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 12.09% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Dec 2025, up 71.73% year-over-year, with the annual reading at $9.0 million for FY2025, 71.73% up from the prior year.
  • Share-based Compensation hit $2.3 million in Q4 2025 for Perspective Therapeutics, up from $2.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.4 million in Q2 2025 to a low of $94000.0 in Q1 2021.
  • Historically, Share-based Compensation has averaged $1.1 million across 5 years, with a median of $672000.0 in 2022.
  • Biggest five-year swings in Share-based Compensation: soared 771.34% in 2023 and later plummeted 54.53% in 2024.
  • Year by year, Share-based Compensation stood at $180000.0 in 2021, then surged by 273.33% to $672000.0 in 2022, then increased by 3.12% to $693000.0 in 2023, then surged by 197.26% to $2.1 million in 2024, then increased by 12.09% to $2.3 million in 2025.
  • Business Quant data shows Share-based Compensation for CATX at $2.3 million in Q4 2025, $2.2 million in Q3 2025, and $2.4 million in Q2 2025.